Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital

Journal of Clinical Pharmacy and Therapeutics

Volumn 40, Issue 4, 2015, Pages 447-451

  Tellor, K B ^a   Patel, S ^a   Armbruster, A L ^a   Daly, M W ^b  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

Author keywords

anticoagulation; atrial fibrillation; deep vein thrombosis; rivaroxaban

Indexed keywords

RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMMUNITY HOSPITAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG SAFETY; EMBOLISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM THROMBOSIS; HUMAN; INCIDENCE; JUGULAR VEIN THROMBOSIS; KIDNEY INFARCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEDICATION ERROR; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; RISK REDUCTION; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; HEMORRHAGE; MIDDLE AGED; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBOLISM; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HOSPITALS, COMMUNITY; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIVAROXABAN; STROKE; VENOUS THROMBOEMBOLISM;

EID: 84936986516     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12288     Document Type: Article

References (13)

1. Coumadin®[package insert]. Princeton: Bristol-Myers Squibb Company, 2013.
2. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012; 141: e44S-e88S doi: 10.1378/chest.11-2292.
3. FDA expands use of Xarelto to treat, reduce recurrence of blood clots. Food and Drug Administration Web site. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm. Ac-cessed March 30, 2015.
4. Patel MR, Mahaffey KW, Garg J, et al,. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2010; 365: 883-891. doi: 10.1056/NEJMoa1009638.
5. Büller HR, Prins MH, Lensin AW, et al,. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297. doi: 10.1056/NEJMoa1113572.
6. Bauersachs R, Berkowitz SD, Brenner B, et al,. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med, 2010; 363: 2499-2510. doi: 10.1056/NEJMoa1007903.
7. January CT, Wann LS, Alpert JS, et al,. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol, 2014; 64: e1-e76. doi: 10.1016/j.jacc.2014.03.022.
8. th edition. Chest 2012; 141: 381-453. doi: 10.1378/chest.11-2301.
9. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron, 1976; 16: 31-41.
10. Xarelto® [package insert]. Princeton: Janssen Pharmaceuticals, Inc., 2014.
11. th ed: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e576S-e600S. doi: 10.1378/chest.11-2305.
12. Armbruster AL, Buehler KS, Min SH, Riley M, Daly MW,. Evaluation of dabigatran for appropriate of use and bleeding events in a community hospital setting. Am Health Drug Benefits, 2014; 7: 376-384.
13. Gray T, Bertch K, Galt K, et al,. Guidelines for therapeutic interchange-2004. Pharmacotherapy 2005; 25: 1666-1680.